SWOG S0722: Phase II Study of mTOR Inhibitor Everolimus (RAD001) in Advanced Malignant Pleural Mesothelioma (MPM)
Conclusion: Everolimus has limited clinical activity in advanced MPM patients. Additional studies of single-agent everolimus in advanced MPM are not warranted.
Source: Journal of Thoracic Oncology - Category: Cancer & Oncology Tags: Brief Reports Source Type: research
More News: Anemia | Anorexia | Asbestosis | Cancer & Oncology | Chemotherapy | Eating Disorders & Weight Management | Mesothelioma | Study | Toxicology